(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of 15.94% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Dynavax Technologies's revenue in 2025 is $294,621,000.On average, 2 Wall Street analysts forecast DVAX's revenue for 2025 to be $39,675,847,567, with the lowest DVAX revenue forecast at $39,550,963,691, and the highest DVAX revenue forecast at $39,800,731,443. On average, 2 Wall Street analysts forecast DVAX's revenue for 2026 to be $47,920,584,996, with the lowest DVAX revenue forecast at $45,683,482,486, and the highest DVAX revenue forecast at $50,157,687,505.
In 2027, DVAX is forecast to generate $54,922,487,697 in revenue, with the lowest revenue forecast at $50,912,994,794 and the highest revenue forecast at $58,931,980,601.